The tumour is made up from several subgroups of cells (subpopulations) with different features. One of the subset actually drives the progress of the disease, the resistance to therapy and the relapse. This subset is called cancer stem cell-like cells or tumour initiating cells.
When a patient is treated and the cancer cells may be destroyed, then when the compatible diagnostic does not discover any signal, the cancer cells may consist of a population of 109 to 1012 cells. This limit defines the remission stage of a patient. At that stage only the cancer stem cells may survive and colonise into distant organs and generate metastases in time.
Common Conditions:
- Cancer
ONCOSTAT Test Code: 7001 – Measures the chemo-sensitivity / chemo-resistance assessment for cytotoxic drugs, monoclonal antibodies, small molecules that inhibitor specific targets (TKI etc).
ONCOSTAT PLUS Test Codes: 7003a, 7003b, 7003c
(Formerly TU Profile Plus) – Measures the chemo-sensitivity / chemo-resistance assessment for cytotoxic drugs, monoclonal antibodies, small molecules that inhibit specific targets (TKI etc) AND the assessment of natural substances and extracts for anticancer potency.
ONCOSTAT EXTRACTS Test Codes: 7002a, 7002b
(Former TU Profile Extracts) – Measures only the assessment of natural substances and plant extracts for anticancer potency.
Follow-Up Assessments:
ONCOTRACE Test Code: 7006 – Measures the concentration of CTCs and the immune-phenotype control of these cells.
ONCOTRAIL Test Code: 7007
Measures relevant markers for specific type of malignancies i.e.
- BREAST Oncotrail
- PROSTATE Oncotrail
- COLON Oncotrail
- MELANOMA Oncotrail
- LUNG Oncotrail
- SARCOMA Oncotrail
- GASTROINTESTINAL Oncotrail
IMMUNOSTAT Test Code: 7009
Profile of humoral and cellular immunity and cachexia.
This test uses specific cellular markers and cytokine production to detect the type or types of cells that are responsible for the activation or repression of the immune system of a patient.
METASTAT Test Code: 7010
Markers on CTCs that point out the potential organ for relapse.
It can help practitioners in the prognosis of metastases trends in cancer patients and guide them in the choice of appropriate chemotherapy.
NOTICE TO PATIENTS
WellLab practices in the usual practitioner-referral system for pathology laboratories. Patients are highly recommended to seek the supervision and guidance of a qualified healthcare practitioner for the interpretation of any lab results and associated information. WellLab can offer assistance in locating a suitable practitioner.